Skip to main content
Sign In
 

Paul A. Seligman, M.D.


Paul A. Seligman, M.D.
Paul A. Seligman, MD
University of Colorado School of Medicine
  • Professor of Medicine with Tenure
  • Ruth and Ralph Seligman Endowed Professor in Hematology
  • Course Director for MED8014 - Hematology/Oncology

 

 

Major Scientific Interest: 
Cell surface receptors and the cellular proliferation
  
Major Clinical Interest: 
Diagnosis and treatment of nutritional deficiency, breast cancer, nutritional aspects of cancer treatment and prevention

 

 

 

Hematology Research Administration
Contact Information

12700 East 19th Avenue
Room 9122
RC 2 / MS B170
Aurora, CO  80045 
(303)-724-4086 - Phone

 

Paul.Seligman@ucdenver.edu

 

 

Download Curriculum Vitae: Paul A. Seligman, MD

Medical School:  State University of New York at Buffalo School of Medicine, Buffalo, New York

 

Postgraduate training:

1972 - 1973        Intern in Medicine, University of Buffalo Affiliated Hospitals, Buffalo, NY

1973 - 1975        Resident in Medicine, University of Buffalo Affiliated Hospitals, Buffalo, NY

1975 - 1978        Fellow in Hematology/Oncology, Washington University School of Medicine, St. Louis, MO

 

 

Past and current professional positions:

1978-1984     Assistant Professor of Medicine, University of Colorado School of Medicine, Denver, CO

1983-2006     Director/Preceptor -Specific elective course in Hospice Medicine For Senior Medical Students

1984-1991     Associate Professor of Medicine, University of Colorado School of Medicine, Denver, CO

1984-Present  Medical Director - Hospice of St. John

1988- 2007    Course Director Medicine 7000 - Clerkship in Internal Medicine For Junior Medicine Students

1988-2006     Director - Medicine elective courses For Senior Medical Students

1991-Present  Professor of Medicine, University of Colorado School of Medicine, Denver, CO

1994-2001     Coordinator of Medical School Curriculum - Chair of Curriculum Committee and Curriculum Review Committee University of Colorado School of Medicine

2001-2003     Coordinator of Fourth Year Curriculum - University of Colorado School of Medicine

2004-Present  Received Endowed Chair-Ruth and Ralph Seligman Endowed Chair in Hematology Research

Dr. Seligman continues work on several themes in his active research laboratory.  He has published extensively on how iron controls cancer cell proliferation.  These ongoing studies have clinical implications in future treatment of neuroblastoma, breast cancer and acute leukemia.  He is also continuing work on a unique molecule purified from plant that inhibits the growth of breast cancer cells in vitro and in vivo. 

  1. Siriwardana G and Seligman PA.  Two cell cycle blocks caused by iron chelation of neuroblastoma cells: separating cell cycle events associated with each block.  Physiological Reports, e00176: 1-9, 2013.
  2. Singh M, Capocelli KE, Marks JL, Schleicher RB, Finlayson CA, Seligman PA.  Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.  Appl Immunohistochem Mol Morphol 13:147-156, 2005.  (PMID: 15894927).
  3. Seligman PA, Dahl NV, Strobos J, Kimko HC, Schleicher RB, Jones M, Ducharme MP. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects.  Pharmacotherapy 24:574-583, 2004.  (PMID: 15162891).
  4. Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, Seligman PA. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 42:325-330, 2003.  (PMID: 12900815).
  5. Seligman PA, Massey E, Fink RS, Nelson-Marten P, von Lobkowitz P.  Practicing physicians' assessments of the impact of their medical-school clinical hospice experience.  J Cancer Educ 14:144-147, 1999.  (PMID: 10512330).
  6. Allen J, Backstrom KR, Cooper JA, Cooper MC, Detwiler TC, Essex DW, Fritz RP, Means RT Jr, Meier PB, Pearlman SR, Roitman-Johnson B, Seligman PA. Measurement of soluble transferrin receptor in serum of healthy adults.  Clin Chem 44:35-39, 1998.  (PMID: 9550555).
  7. Seligman PA, Schleicher RB, Siriwardana G, Domenico J, Gelfand EW. Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation.   Blood 82:1608-1617, 1993.  (PMID: 8364209).
  8. Seligman PA, Crawford ED. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate.  J Natl Cancer Inst 83:1582-1584, 1991.  (PMID: 1960756).
  9. Seligman PA, Kovar J, Schleicher RB, Gelfand EW. Transferrin-independent iron uptake supports B lymphocyte growth.  Blood 78:1526-1531, 1991.  (PMID: 1884019).
  10. Seligman PA, Caskey JH, Frazier JL, Zucker RM, Podell ER, Allen RH.  Measurements of iron absorption from prenatal multivitamin--mineral supplements.  Obstet Gynecol 61:356-362, 1983.  (PMID: 6823378).
  11. Seligman PA, Schleicher RB, Allen RH. Isolation and characterization of the transferrin receptor from human placenta.  J Biol Chem. 25:9943-9946, 1979.  (PMID: 226547).